Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Float traded over how many times yesterday? Crazy. Good news but time would be the hold back. The good part of that is, there is plenty of time since they've already done their RS and regained compliance.
Volatility here is going to be nuts for a while imo.
This has plenty of running room if it could just find the momentum.
Looks pretty ripe to me!!!
This should be well over the $ imo.
Thinking the fuse has been lit!
Let's see some volume!!!
I've seen volume come out of nowhere on set ups just like this. News to draw in a few bulls would certainly help!!
Was just looking at VSTM, looks like they have a couple catalysts coming up by the end of year but sure had its price attacked like crazy.
NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1
NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1
FDA Expands the Scope of the Company's Submission
Accelerates Path Toward Immunotherapy for Glioblastoma (Brain Cancer)
CLEVELAND, OH / ACCESSWIRE / October 26, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the approval of its application with the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation (ODD) for TLR-AD1, a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas.
https://finance.yahoo.com/news/novaccess-global-receives-fda-approval-110000523.html
Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022
THE WOODLANDS, Texas, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two oral presentations relating to its investigational drug LX9211 will be delivered virtually during the World Brain Disorders and Neuroscience Summit 2022 Hybrid in Munich, Germany:
“Evaluation of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain: Study Design and Topline Results from the RELIEF-DPN-1 Trial”, describes the positive results achieved in this proof-of-concept study and will be given on Saturday, October 29th at 3:25pm CEST/9:25am ET.
“Evaluation of LX9211, a Potent, Selective Inhibitor of AAK1, in Preclinical Models of Spasticity”, describes the effect of LX9211 in reducing spasticity in established animal models and will be given on Monday, October 31st at 3:35pm CET/8:35am ET.
https://finance.yahoo.com/news/lexicon-pharmaceuticals-announces-oral-presentations-125900260.html
Looks to be waking up.
LXRX chart
NovAccess Global Announces Fireside Chat with Board Member Perspectives
9:18 am ET October 20, 2022 (Accesswire) Print
Topic: Opportunities for the Biomedical Field and for Shareholders
CLEVELAND, OH / ACCESSWIRE / October 20, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the availability of its initial installment in a series of interviews with its corporate leadership on a monthly basis for the next four months, with additional sessions to be made available as company developments arise. Interviews are intended to cover important and timely topics relating to the Company, its platform technologies and the global healthcare and business environments.
The initial fireside chat includes interview with select Executive and Non-Executive members of the Company's Board of Directors. The interview is being streamed for public viewing over the Internet and can be accessed via the News tab of the Investors section of the NovAccess Global website at https://novaccessglobal.com/news/ and on all of the Company's social media feeds.
During the interview made available today, Company speakers address:
NovAccess Global advancing where no measurable survivability and quality of life improvements have been achieved in 50 years for glioblastoma/brain tumors
Significant unmet need in the glioblastoma/brain tumor market
Progress pathways for NovAccess Global's novel lead product TLR-AD1, including IND and FDA data submissions
Representing a new class of immunotherapies shaping the industry
Enhanced response and survival potential using the Company's patented platform-based immune booster technology
Driving efficiencies with check point inhibitors for improving tumor treatment outcomes
Aggressive timeline set to achieve inflection points of safety and efficacy for lead product
Licensing opportunities for various cancer treatments
Accelerating healthcare innovation through technology transfer
Exponential value creation potential for investors available through NovAccess Global
Speaker Bios:
Dr. Dwain Irvin, Ph.D., MPH, CEO and Executive Board Member of NovAccess Global -- Dr. Irvin is an active participant in many Biotechnology and Health Science endeavors and is an expert including patent generation in such areas as treatments for Parkinson's, brain cancer, and even cosmetic application of advanced bioscience. He is also an expert in the physical operations of laboratories, and hospitals. He received his Ph.D. from UCLA School of Medicine, and Masters in Public Health from UCLA School of Public Health, and trained at The Wallenberg Neuroscience Center at Lund University in Lund, Sweden. He was also a Professor, Faculty member at Cedars-Sinai Medical Center, Department of Neurosurgery.
Dr. Irvin's Ph.D. is in Pharmacology and Developmental Neuroscience with an emphasis on neural stem cell fate and differentiation. His research focused on neural development and Notch Signaling in mammalian neural stem cells.
He also worked as an NIH/NINDS Post-Doctoral Fellow in Dr. Anders Bjorklund laboratory in Lund, Sweden. There, his focus was on research projects that investigated the potential role of cell replacement therapy for patients with Parkinson's disease. They developed several protocols for the efficient generation of dopaminergic neurons from forebrain and ventral midbrain stem and progenitor cells.
Additionally, Dr. Irvin led research investigations in the role of adaptive immunity in Parkinson's disease. He also developed two patents in the area of immunotherapy for brain tumor patients, specifically Glioblastoma Multiforme (GBM). His research team focused on molecular mechanisms that impart therapeutic resistance in cancer cells, including cancer stem cells. They utilized this data to develop novel immunotherapies for brain tumor patients.
John Cassarini, Board Member of NovAccess Global -- Mr. Cassarini has spent the last three decades working with and investing in small-cap companies. He began his career on Wall Street as an Associate in the Equity Research Department of Smith Barney. Later, he joined Smith Barney's parent company, the Travelers Corporation, as an analyst responsible for private and public investments in emerging businesses. In addition, he worked as a portfolio manager at several institutions, including Ingalls & Snyder, Lehman Brothers, and Barclays Capital, managing funds focused on small emerging growth companies.
Mr. Cassarini graduated from Fordham University with a bachelor's degree in finance and a master's degree in business administration from Columbia University.
Jason Anderson, Board Member of NovAccess Global --Mr.Anderson is experienced in the fields of biological discovery, genomic modeling, drug development, and national security. From 2016-2020, he was a co-founder and member of the board of EdenRoc Sciences, LLC, a privately-held biotechnology company formed to cultivate world-class life sciences start-up companies to include Liberty BioSecurity, LLC, where he served as co-founder and Chief Executive Officer from 2014-2020. This integrated life sciences platform leveraged a dynamic intellectual property portfolio spanning pharmaceuticals, novel biology, genomics, and molecular diagnostics.
From 1998 to 2014, Mr. Anderson served as a diplomat for the United States Department of State. He has co-authored several granted patents in the life sciences and speaks on international affairs and biotechnology innovation. He is a graduate of the London School of Economics and Political Science and the University of California, San Diego, and speaks Spanish and Chinese (Mandarin).
NovAccess Global Fireside Chat Series Schedule:
The series will include interviews on a monthly basis over the next four months. Interviews will be made available by NovAccess Global as detailed below:
October 6, 2022 - NovAccess Global Board Member Perspectives - Opportunities for the Biomedical Field and for Shareholders
Speakers: Select Executive and Non-Executive members of the Company's Board of Directors
November 3, 2022 - Patient Advocacy
Speaker: Dr. Dwain Irvin, Ph.D., MPH, CEO of NovAccess Global
December 1, 2022 - Immunotherapy Advantages Over Surgical Treatment
Speaker:Dr. Christopher Wheeler, Ph.D., President of StemVax Therapeutics Inc., a division of NovAccess Global
January 5, 2023 - The Glioblastoma and Brian Tumor Market
Speaker: Dr. Dwain Irvin, Ph.D., MPH, CEO of NovAccess Global
The interviews will be streamed for public viewing over the Internet and can be accessed on the dates provided in this press release through links made available on the NovAccess Global website at www.novaccessglobal.com and on all of the Company's social media feeds.
About NovAccess Global
NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.
NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our Company has a novel immunotherapeutic approach to treating brain tumor patients with glioblastoma, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. It is a meaningful technology that could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit novaccessglobal.com.
Forward-Looking Statement
This press release contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the Company's disclosures or filings with the Securities Exchange Commission. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess Global Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.
This press release and the interviews to be published as part of the NovAccess Global fireside chat series are for informational purposes only and should not be considered investment advice, an offer to sell, or a solicitation of an offer to buy any security. Interview participants have agreed to participate in this event series and no compensation will be paid or furnished to them or their respective organizations. Participation does not represent an offer to buy or sell any security to or from any person or other entity through their platforms. Prior to making any investment or subscribing to any of the platforms that may be associated with the fireside chat series and re-distribution of related content, listeners/viewers are encouraged to consult with professional financial, legal advisor and tax advisors to assist in due diligence as may be appropriate in determining the risk associated with any investment.
Investor Relations Contact:
Jordan Darrow
Darrow Associates
631-766-4528
jdarrow@darrowir.com
SOURCE: NovAccess Global Inc.
$TELL looks fairly similar to $WATT. See if they get the bolinger squeeze son.
Watching the psar, just broke .35 resistance, legs to .60's possible imo.
Crazy!!! LII's are nuts!
Big blocks on both sides. Looks to be basing again .332's. Like to get more than just a .02 flip.
lmao
Intraday support .34's. This could grow some legs.
Amazes me how fast these can top and then crash. INPX already down over $2, RMED following soon. I suspect KPRX will be back near 6 in a day or 2. Gotta be quick with these ATM's.
There's like no float on KPRX. Crazy. Split themselves pretty hard to do that. Other recent RS plays are INPX & RMED.
Of course they can kill you if you're on them when they crash and burn.
SYSX just popped up on my pincher radar. The dilution will likely kill it.
SYSX just popped up on my pincher radar. The dilution will likely kill it.
Lmao
Possibly finding a base.
Soligenix Enters Q4 With Multiple Catalysts in Play
Newsfile Corp.
Thu, October 13, 2022 at 5:30 AM·4 min read
In this article:
New York, New York--(Newsfile Corp. - October 13, 2022) - PCG Digital -- Late-stage biopharmaceutical company, Soligenix, Inc. (NASDAQ: SNGX) is anticipating significant catalysts in Q4 and a potentially transformational year in 2023.
https://finance.yahoo.com/news/soligenix-enters-q4-multiple-catalysts-123000437.html
They've also hired Chesapeake Group. Contact info is on the PR.
https://chesapeakegp.com/
Their the only reason I even heard of this ticker. And nope, not buying anytime soon.
https://finance.yahoo.com/news/kulr-hosting-booth-2022-equip-203000198.html
If money isn't going into the stock market.... where's it going?
Mattresses.
Again.
Look out.
Read the 8K and understand the dilution this is facing and the discount they get. Yes, this is toxic funding. Only if they can somehow manage to keep retail buying until they're out, I do expect this to depreciate. Possibly significantly.
ONTX .91 another low volume take down setting up for a possible pinch.
ONTX daily
This HARDLY has the volume to attract that BS. But still, the MM's are letting it happen.
%$#@ers!!!
Thinking .01 until they file their IND. 35% discount on their financing with a 15 day VWAP, it won't take long to tank this.
Whelp, welcome to the dark side.
https://ih.advfn.com/stock-market/USOTC/novaccess-global-qb-XSNX/stock-news/89178972/current-report-filing-8-k
Gold Pinned Above $1,650, But Recovery Stalls as Dollar Steadies
By Ambar Warrick
Investing.com-- Gold prices fell slightly on Thursday after recovering sharply from multi-year lows, as markets remained wary of another resurgence in the dollar and Treasury yields.
Spot gold prices fell 0.3% to $1,655.86 an ounce, while gold futures fell 0.3% to $1,664.35 an ounce by 19:35 ET (23:35 GMT). Both instruments surged nearly 2% on Wednesday, logging their best day in two months.
An easing dollar and Treasury yields came as a major boost to metal markets on Wednesday, with the greenback retreating sharply from a 20-year high, while 10-year U.S. Treasury yields fell from a 12-year peak.
https://finance.yahoo.com/news/gold-pinned-above-1-650-201031215.html
Does look like the $ may have topped.
https://finviz.com/futures_charts.ashx?p=d1&t=DX
MAYBE there's a hint that we'll see some stabilization but I have my doubts that the almost 1000 point intraday volatility is coming to an end anytime soon. What Erin didn't mention in the article you posted was the action of the VIX back in the bear market of 2020. Take a look at the weekly...
https://finviz.com/futures_charts.ashx?t=VX&p=w1
and then back to our current daily...
https://finviz.com/futures_charts.ashx?t=VX&p=d1 One could say that this is just the start of a cup and handle forming before the major volatility takes shape. While we can see the DJIA move 1000 points during the day, it may close in either direction. I don't think the bears are even close to heading into hibernation. The next few weeks should be very interesting.
https://novaccessglobal.com/news/ Some good stuff in there. And now they're OTCQB. Looking for their IND soon.
Also...
Keep an eye on the weekly charts. About another 1000 pts should do it. Maybe.
https://finviz.com/futures_charts.ashx?t=YM&p=w1
Wow, already about to the $. That didn't take long at all.
This is an excellent overall sentiment...
Posted by Discovergold. Worth the read.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170010398
https://www.clivemaund.com/free.php?id=6241
So far my (and probably MANY others) have set a course for the bear market to continue for some time.
Sept 2nd about the $
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169856759
And the $ is still punching thru resistance.
My rambling on Spt 7th..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169885832
Market whiplash will continue for some time imo.
Good luck out there!!
They didn't call me!! lol voting closed Sept 14th looks like.
So, bottom around .50?
And this is how you blow up the float...
Watch these guys...
https://www.sec.gov/Archives/edgar/data/1646799/000121390022054053/ea165367-13gintra_baudax.htm
6 different warrants.
https://whalewisdom.com/filer/intracoastal-capital-llc
Still, the float (even after all the warrants) IMO is too small for a RS. I think, with the potential to regain compliance by their deadline in January, this firm just may make something happen...
Intracoastal Capital LLC
https://www.intercoastalcap.com/company/
https://www.sec.gov/Archives/edgar/vprr/2100/21004752.pdf
parent company Trifecta Group Holdings LLC
https://www.trifectagroup.com/
Bears are on the job. eom
LXRX chart
My wife tells me the same thing. But I do like the technicals. As an engineering type I can really get into the charts. Sometimes the fundamentals are also worth the risk. We'll see. Soligenix posted an ROCE of -0.57%.
I was Carrier precom, sub tenders and shore sub/ship repair Pacific, East Coast and Scotland. I'll PM you during happy hour.
Lol. I'll be collecting 2 retirements by that time. When this gets back over the $ it'll fatten the account just nicely.